Syncom Formulations (India) Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
SYNCOMF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Syncom Formulations reported its Q3 FY26 (Oct–Dec 2025) and nine-month FY26 results along with a clean (unmodified) limited review report from auditors Sanjay Mehta & Associates. Standalone revenue from operations for Q3 came in at Rs. 11,459 lakhs, down about 9.8% from Rs. 12,703 lakhs in Q3 last year, while for the nine months it grew roughly 12% to Rs. 35,257 lakhs (from Rs. 31,439 lakhs). Despite the quarterly revenue dip, profit after tax jumped to Rs. 1,886 lakhs in Q3 (+47% YoY) and Rs. 5,143 lakhs for 9M FY26 (+64% YoY), driven mainly by a sharp fall in raw material costs. EPS for 9M FY26 stood at Rs. 0.61 vs Rs. 0.41 a year ago. The company also disclosed a new GST-related demand of about Rs. 4.42 crore (tax + penalty) which it plans to contest in appeal.
Strong profit growth and margin expansion are positives for shareholders, but the year-on-year revenue decline in the latest quarter and the fresh Rs. 4.42 crore GST demand (contingent liability) are watch-items that could weigh on the stock. Overall, the results are a mixed bag — better-than-expected profitability but softening top line and a new tax dispute.